Treatment implications of augmented renal clearance in a critically ill COVID‐19 patient: A case report

Abstract

Augmented renal clearance (ARC) is a pathophysiological phenomenon that can occur in critically ill patients, leading to enhanced renal function. It is defined as a creatinine clearance of >130 mL/min/1.73 m2. ARC can lead to subtherapeutic levels of renally cleared drugs and subsequent treatment failure. In COVID‐19, it has only been described in the literature in a few cases. We present the case of a 38‐year‐old critically ill patient with COVID‐19 who developed ARC with an initial clearance of 226 mL/min/1.73 m2, persisting for 30 days. He required high doses of sedatives and neuromuscular blocking agents, as well as increased doses of vancomycin and dalteparin, to reach adequate serum levels. This case emphasizes the importance for clinicians to consider ARC in the dosing of all renally cleared drugs, including antibiotics, low molecular weight heparins, and sedatives, to prevent subtherapeutic drug levels and treatment failure.

LC-MS/MS-Based Serum Metabolomics and Transcriptome Analyses for the Mechanism of Augmented Renal Clearance

“…ARC often occurs in critically ill people with ailments such as burns, sepsis, cancer, multiple injuries, and subarachnoid hemorrhaging [ 4 , 5 , 6 , 7 ]. ARC has also been reported in patients with coronavirus disease 2019 (COVID-19) [ 8 , 9 , 10 ]. The incidence of ARC in these populations can be up to 85% [ 1 , 2 , 11 , 12 , 13 , 14 , 15 , 16 ].…”